Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine

DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, today announced that Degroof Petercam, a brokerage firm and investment bank, has initiated coverage of its shares. In its initiation study entitled “Targeted therapies for inflammation & oncology”, Degroof Petercam began covering the stock by rendering i